REPYF (REPYF)

Insperity (NSP) is back in focus after its second quarter 2026 earnings release, which showed modest sales growth, a return to quarterly profitability, fresh guidance, and new capital actions including share repurchases and a shelf registration. See our latest analysis for Insperity.

S&P 500 earnings roundup: big beats/misses from MSFT, AMZN, AAPL, META, QCOM, BA, XOM & more—plus next week’s key reports.

The panel voted 10-3 that the results from a key clinical study of the company’s therapy, known as RP1, were both reliable and clinically meaningful for certain patients with advanced melanoma. RP1 faced two prior FDA rejections.The FDA’s new decision on

The womenswear brand raised $210.9 million in its IPO, pricing at the low end of its projected range

Retailer Reformation made its IPO on the New York Stock Exchange on Thursday under the ticker symbol "REF."